The relation of adipose tissue to cardiometabolic risk

Clinical Cornerstone

Volumn 8, Issue SUPPL. 4, 2006, Pages

  Xavier Pi Sunyer, F ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CYTOKINE; ENZYME INHIBITOR; INTERLEUKIN 6; LEPTIN; LIPASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; RIMONABANT; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADIPOCYTE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; HEART PROTECTION; HORMONE ACTION; HUMAN; INFLAMMATORY DISEASE; INTRAABDOMINAL FAT; LIFESTYLE MODIFICATION; METABOLIC DISORDER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PLEIOTROPY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REGULATORY MECHANISM; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; WEIGHT REDUCTION;

ADIPOCYTES; ADIPONECTIN; ADIPOSE TISSUE; ATHEROSCLEROSIS; CYTOKINES; HUMANS; RISK FACTORS;

EID: 33845964266     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1098-3597(06)80040-2     Document Type: Article

References (53)

1. Eckel R.H., Kahn R., Robertson R.M., et al. Preventing cardiovascular disease and diabetes: A call to action from the American Diabetes Association and the American Heart Association. Circulation 113 (2006) 2943-2946
2. Kyoto, Japan. Grundy S.M. Genetics, obesity, and the metabolic syndrome: The Professor Donald S. Fredrickson Memorial Lecture. Proceedings of the 13th International Symposium (September 28-October 2, 2004)
3. Semenkovich C.F. Insulin resistance and atherosclerosis. J Clin Invest. 116 (2006) 1813-1822
4. Manson J.E., Colditz G.A., Stampfer M.J., et al. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med. 322 (1990) 882-889
5. Wilson P.W., D'Agostino R.B., Sullivan L., et al. Overweight and obesity as determinants of cardiovascular risk: The Framingham experience. Arch Intern Med. 162 (2002) 1867-1882
6. McCance D.R., Pettitt D.J., Hanson R.L., et al. Glucose, insulin concentrations and obesity in childhood and adolescence as predictors of NIDDM. Diabetologia 37 (1994) 617-623
7. Chan J.M., Rimm E.B., Colditz G.A., et al. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 17 (1994) 961-969
8. Colditz G.A., Willett W.C., Rotnitsky A., et al. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 122 (1995) 481-486
9. Frühbeck G., Nutr R., and Salvador J. Role of adipocytokines in metabolism and disease. Nutrition Res. 24 (2004) 803-826
10. Rum H., and Lodish H.E. Insulin resistance in adipose tissue: Direct and indirect effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev. 14 (2003) 447-455
11. quiz 920. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 115 (2005) 911-919
12. Kershaw E.E., and Flier J.S. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 89 (2004) 2548-2556
13. Frühbeck G., Gomez-Ambrosi J., Mumzabal F.J., et al. The adipocyte: A model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metab. 280 (2001) E827-E847
14. Kahn B.B., and Flier J.S. Obesity and insulin resistance. J Clin Invest. 106 (2000) 473-481
15. Rajala M.W., and Scherer P.E. Minireview: The adipocyteat the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 144 (2003) 3765-3773
16. Ailhaud G. Adipose tissue as a secretory organ: From adipogenesis to the metabolic syndrome. C R Biol. 329 (2006) 570-577
17. Havel P.J. Control of energy homeostasis and insulin action by adipocyte hormones: Leptin, acetylation stimulating protein, and adiponectin. Curr Opin Lipidol. 13 (2002) 51-59
18. Mohamed-Ali V., Pinlarney J.H., and Coppack S.W. Adipose tissue as an endocrine and paracrine organ. Int J Obes. 22 (1998) 1145-1158
19. Shimomura I., Funahashi T., Takahashi M., et al. Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity. Nat Med. 2 (1996) 800-803
20. Hotamisligil G.S., Armer P., Caro I.F., et al. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest. 95 (1995) 2409-2415
21. Trayhurn P., and Wood I.S. Signalling role of adipose tissue: Adipokines and inflammation in obesity. Biochem Soc Trans. 33 (2005) 1078-1081
22. Lyon C.J., Law R.E., and Hsueh W.A. Minireview: Adiposity, inflammation, and atherogenesis. Endocrinology 144 (2003) 2195-2200
23. Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett. 580 (2006) 2917-2921
24. Arita Y., Kihara S., Ouchi N., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 257 (1999) 79-83
25. Cnop M., Havel P.L., Utzschneider K.M., et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: Evidence for independent roles of age and sex. Diabetologia 46 (2003) 459-469
26. Trayhurn P., and Wood I.S. Adipokines: Inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 92 (2004) 347-355
27. Nawrocki A.R., and Scherer P.E. The delicate balance between fat and muscle: Adipokines in metabolic disease and musculoskeletal inflammation. Curr Opin Pharmacol. 4 (2004) 281-289
28. Greenberg A.S., and Obin M.S. Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr. 83 (2006) 4615-4655
29. Matsuzawa Y., Funahashi T., Kihara S., et al. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 24 (2004) 29-33
30. Ouchi N., Shibata R., and Walsh K. Cardioprotection by adiponectin. Trends Cardiovasc Med. 16 (2006) 141-146
31. Gable D.R., Hurel S.L., and Humphries S.E. Adiponectin and its gene variants as risk factors for insulin resistance, the metabolic syndrome and cardiovascular disease. Atherosclerosis 188 (2006) 231-244
32. Ouchi N., Kihara S., Arita Y., et al. Novel modulator for endothelial adhesion molecules: Adipocyte-derived plasma protein, adiponectin. Circulation 100 (1999) 2473-2476
33. Shibata R., Sato K., Pimentel D.R., et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med. 11 (2005) 1096-1103
34. Hotta K., Funahashi T., Arita Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 20 (2000) 1595-1599
35. Cote M., Mauriege P., Bergeron J., et al. Adiponectinemia in visceral obesity: Impact on glucose tolerance and plasma lipoprotein and lipid levels in men. J Clin Endocrinol Metab. 90 (2005) 1434-1439
36. Otero M., Lago R., Lago F., et al. Leptin, from fat to inflammation: Old questions and new insights. FEBS Lett. 579 (2005) 295-301
37. Otero M., Lago R., Gomez R., et al. Leptin: A metabolic hormone that functions like a proinflammatory adipokine. Drug News Perspect. 19 (2006) 21-26
38. Wiman B., Chmielewska J., and Ranby M. Inactivation of tissue plasminogen activator in plasma: Demonstration of a complex with a new rapid inhibitor. J Biol Chem. 259 (1984) 3644-3647
39. Alessi M.C., Lijnen H.R., Bastelica D., et al. Adipose tissue and atherothrombosis. Pathophysiol Haemost Thromb. 33 (2003/2004) 290-297
40. Park H.S., Park J.Y., and Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNFalpha and IL-6. Diabetes Res Clin Pract. 69 (2005) 29-35
41. Pi-Sunyer F.X. The epidemiology of central fat distribution on relation to disease. Nutr Rev. 62 (2004) S120-S126
42. Pouliot M.C., Despres J.P., Nadeau A., et al. Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes 41 (1992) 826-834
43. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
44. Hamalainen H., Ronnemaa T., Virtanen A., et al., Finnish Diabetes Prevention Study Group. Improved fibrinolysis by an intensive lifestyle interven tion in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia 48 (2005) 2248-2253
45. Milano W., Penella C., Casella A., et al. Use of sibutramine, an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge eating disorder: A placebocontrolled study. Adv Ther. 22 (2005) 25-31
46. Valsamakis G., McTernan P.G., Chetty R., et al. Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism 53 (2004) 430-434
47. Williams C.M., and Kirkham T.C. Anandamide induces overeating: Mediation by central cannabinoid (CBI) receptors. Psychopharmacology (Berl) 143 (1999) 315-317
48. Bensaid M., Gary-Bobo M., Esclangon A., et al. The cannabinoid CBI receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mot Pharmacol. 63 (2003) 908-914
49. Liu Y.L., Connoley I.F., Wilson C.A., et al. Effects of the cannabinoid CBI receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/ Lep(ob) mice. Int J Obes. 29 (2005) 183-187
50. Osei-Hyiaman D., Depetrillo M., Pacher P., et al. Endocannabinoid activation at hepatic CB(1) receptors stimulates fatty acid synthesis and contributes to dietinduced obesity. J Clin Invest. 115 (2005) 1298-1305
51. Pi-Sunyer F.X., Aronne L.L., Heshmati H.M., et al., RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardio metabolic risk factors in overweight or obese patients: RIO-North America: A randomized controlled trial. JAMA 295 (2006) 761-775
52. Van Gaal L.F., Rissanen A.M., Scheen Al., et al., RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-Year experience from the RIO-Europe study. Lancet 365 (2005) 1389-1397
53. Després J.P., Golay A., Sjostrom L., et al., Rimonabant in Obesity Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 353 (2005) 2121-2134